Related references
Note: Only part of the references are listed.Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis
Nicola De Stefano et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2016)
Switching from natalizumab to fingolimod A randomized, placebo-controlled study in RRMS
Ludwig Kappos et al.
NEUROLOGY (2015)
Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis
Ernst-Wilhelm Radue et al.
NEUROLOGY (2015)
Long-term effects of fingolimod in multiple sclerosis The randomized FREEDOMS extension trial
Ludwig Kappos et al.
NEUROLOGY (2015)
Tissue Distribution Dynamics of Human NK Cells Inferred from Peripheral Blood Depletion Kinetics after Sphingosine-1-Phosphate Receptor Blockade
M. Mehling et al.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY (2015)
The sphingosine 1-phosphate receptor agonist FTY720 is neuroprotective after cuprizone-induced CNS demyelination
A. Slowik et al.
BRITISH JOURNAL OF PHARMACOLOGY (2015)
Sphingosine 1 Phosphate at the Blood Brain Barrier: Can the Modulation of S1P Receptor 1 Influence the Response of Endothelial Cells and Astrocytes to Inflammatory Stimuli?
Simona F. Spampinato et al.
PLOS ONE (2015)
Fingolimod treatment promotes regulatory phenotype and function of B cells
Berit Gruetzke et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2015)
Treatment Effect on Brain Atrophy Correlates with Treatment Effect on Disability in Multiple Sclerosis
Maria Pia Sormani et al.
ANNALS OF NEUROLOGY (2014)
Fingolimod increases brain-derived neurotrophic factor levels and ameliorates amyloid β-induced memory impairment
Kazuya Fukumoto et al.
BEHAVIOURAL BRAIN RESEARCH (2014)
Clinical Relevance of Brain Volume Measures in Multiple Sclerosis
Nicola De Stefano et al.
CNS DRUGS (2014)
Systemic distribution, Subcellular localization and differential expression of sphingosine-1-phosphate receptors in benign and malignant human tissues
Chunyi Wang et al.
EXPERIMENTAL AND MOLECULAR PATHOLOGY (2014)
Mechanisms of White Matter Damage in Multiple Sclerosis
Hans Lassmann
GLIA (2014)
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial
Peter A. Calabresi et al.
LANCET NEUROLOGY (2014)
Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy
G. Francis et al.
MULTIPLE SCLEROSIS JOURNAL (2014)
The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis
Frederik Barkhof et al.
MULTIPLE SCLEROSIS JOURNAL (2014)
Fingolimod after natalizumab and the risk of short-term relapse
Vilija G. Jokubaitis et al.
NEUROLOGY (2014)
Immunohistochemical detection of sphingosine-1-phosphate receptor 1 and 5 in human multiple sclerosis lesions
C. Brana et al.
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY (2014)
Investigation of immune and CNS-mediated effects of fingolimod in the focal delayed-type hypersensitivity multiple sclerosis model
Daniel C. Anthony et al.
NEUROPHARMACOLOGY (2014)
Fingolimod Attenuates Splenocyte-Induced Demyelination in Cerebellar Slice Cultures
Adam J. Pritchard et al.
PLOS ONE (2014)
Compositional Changes of B and T Cell Subtypes during Fingolimod Treatment in Multiple Sclerosis Patients: A 12-Month Follow-Up Study
Nele Claes et al.
PLOS ONE (2014)
Switching From Natalizumab to Fingolimod in Multiple Sclerosis A French Prospective Study
Mikael Cohen et al.
JAMA NEUROLOGY (2014)
Fingolimod in relapsing multiple sclerosis: An integrated analysis of safety findings
Ludwig Kappos et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2014)
Insufficient OPC migration into demyelinated lesions is a cause of poor remyelination in MS and mouse models
Amanda Boyd et al.
ACTA NEUROPATHOLOGICA (2013)
The astrocyte in multiple sclerosis revisited
Celia F. Brosnan et al.
GLIA (2013)
Fingolimod phosphate promotes the neuroprotective effects of microglia
Hiromi Noda et al.
JOURNAL OF NEUROIMMUNOLOGY (2013)
Dual effects of daily FTY720 on human astrocytes in vitro: relevance for neuroinflammation
Celina Wu et al.
JOURNAL OF NEUROINFLAMMATION (2013)
Fingolimod: Direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy
Aran Groves et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2013)
Origins and significance of astrogliosis in the multiple sclerosis model, MOG peptide EAE
Monica Moreno et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2013)
Microglia Multiple roles in surveillance, circuit shaping, and response to injury
Eduardo E. Benarroch
NEUROLOGY (2013)
Remyelination Therapy for Multiple Sclerosis
Michael B. Keough et al.
NEUROTHERAPEUTICS (2013)
Fingolimod Phosphate Attenuates Oligomeric Amyloid β-Induced Neurotoxicity via Increased Brain-Derived Neurotrophic Factor Expression in Neurons
Yukiko Doi et al.
PLOS ONE (2013)
FTY720 Treatment in the Convalescence Period Improves Functional Recovery and Reduces Reactive Astrogliosis in Photothrombotic Stroke
Robert Brunkhorst et al.
PLOS ONE (2013)
Fingolimod protects cultured cortical neurons against excitotoxic death
Luisa Di Menna et al.
PHARMACOLOGICAL RESEARCH (2013)
The role of natural killer cells in multiple sclerosis and their therapeutic implications
Coralie Chanvillard et al.
FRONTIERS IN IMMUNOLOGY (2013)
Fingolimod attenuates ceramide-induced blood-brain barrier dysfunction in multiple sclerosis by targeting reactive astrocytes
Ruben van Doorn et al.
ACTA NEUROPATHOLOGICA (2012)
Sphingosine-1-Phosphate and Lymphocyte Egress from Lymphoid Organs
Jason G. Cyster et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 30 (2012)
Impact of Fingolimod Therapy on Magnetic Resonance Imaging Outcomes in Patients With Multiple Sclerosis
Ernst-Wilhelm Radue et al.
ARCHIVES OF NEUROLOGY (2012)
Oral fingolimod rescues the functional deficits of synapses in experimental autoimmune encephalomyelitis
S. Rossi et al.
BRITISH JOURNAL OF PHARMACOLOGY (2012)
Clinical Pharmacokinetics of Fingolimod
Olivier J. David et al.
CLINICAL PHARMACOKINETICS (2012)
S1P1 receptor subtype inhibits demyelination and regulates chemokine release in cerebellar slice cultures
Graham K. Sheridan et al.
GLIA (2012)
Anti-CD20 Therapy Reduces Microglial Activation and Lesion Volume in Focal Models of Pattern I and Pattern II Multiple Sclerosis (P02.085)
D. Leppert et al.
NEUROLOGY (2012)
Fingolimod, a sphingosine-1 phosphate receptor modulator, increases BDNF levels and improves symptoms of a mouse model of Rett syndrome
Ruben Deogracias et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Cells of the oligodendroglial lineage, myelination, and remyelination
Veronique E. Miron et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2011)
BZM055, an Iodinated Radiotracer Candidate for PET and SPECT Imaging of Myelin and FTY720 Brain Distribution
Emmanuelle Briard et al.
CHEMMEDCHEM (2011)
Neurobiological effects of sphingosine 1-phosphate receptor modulation in the cuprizone model
Hye Jung Kim et al.
FASEB JOURNAL (2011)
Reduction of the Peripheral Blood CD56bright NK Lymphocyte Subset in FTY720-Treated Multiple Sclerosis Patients
Trina A. Johnson et al.
JOURNAL OF IMMUNOLOGY (2011)
Differential responses of human microglia and blood-derived myeloid cells to FTY720
Bryce A. Durafourt et al.
JOURNAL OF NEUROIMMUNOLOGY (2011)
Fingolimod modulates microglial activation to augment markers of remyelination
Samuel J. Jackson et al.
JOURNAL OF NEUROINFLAMMATION (2011)
Remyelination Is Altered by Bone Morphogenic Protein Signaling in Demyelinated Lesions
Jennifer K. Sabo et al.
JOURNAL OF NEUROSCIENCE (2011)
Sphingosine 1-phosphate receptor modulator fingolimod (FTY720) does not promote remyelination in vivo
Yinghui Hu et al.
MOLECULAR AND CELLULAR NEUROSCIENCE (2011)
Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS
M. C. Kowarik et al.
NEUROLOGY (2011)
FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation
Ji Woong Choi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Fingolimod (FTY720) Enhances Remyelination Following Demyelination of Organotypic Cerebellar Slices
Veronique E. Miron et al.
AMERICAN JOURNAL OF PATHOLOGY (2010)
Distinct Properties of Circulating CD8+ T Cells in FTY720-Treated Patients With Multiple Sclerosis
Trina A. Johnson et al.
ARCHIVES OF NEUROLOGY (2010)
Functional role of brain-derived neurotrophic factor in neuroprotective autoimmunity: therapeutic implications in a model of multiple sclerosis
Ralf A. Linker et al.
BRAIN (2010)
Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis
Jerold Chun et al.
CLINICAL NEUROPHARMACOLOGY (2010)
Astrocyte-Restricted Ablation of Interleukin-17-Induced Act1-Mediated Signaling Ameliorates Autoimmune Encephalomyelitis
Zizhen Kang et al.
IMMUNITY (2010)
Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis
Volker Brinkmann et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes
N. De Stefano et al.
NEUROLOGY (2010)
Sphingolipids in Multiple Sclerosis
Arundhati Jana et al.
NEUROMOLECULAR MEDICINE (2010)
Intrathecal increase of sphingosine 1-phosphate at early stage multiple sclerosis
Alina Kulakowska et al.
NEUROSCIENCE LETTERS (2010)
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
Ludwig Kappos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
Jeffrey A. Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
The cuprizone animal model: new insights into an old story
Markus Kipp et al.
ACTA NEUROPATHOLOGICA (2009)
The relation between inflammation and neurodegeneration in multiple sclerosis brains
Josa M. Frischer et al.
BRAIN (2009)
FTY720 Rescue Therapy in the Dark Agouti Rat Model of Experimental Autoimmune Encephalomyelitis: Expression of Central Nervous System Genes and Reversal of Blood-Brain-Barrier Damage
Carolyn A. Foster et al.
BRAIN PATHOLOGY (2009)
FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system
Volker Brinkmann
BRITISH JOURNAL OF PHARMACOLOGY (2009)
17β-Estradiol and Progesterone Prevent Cuprizone Provoked Demyelination of Corpus Callosum in Male Mice
Peter Acs et al.
GLIA (2009)
Proof of concept studies for tissue-protective agents in multiple sclerosis
L. R. Mehta et al.
MULTIPLE SCLEROSIS JOURNAL (2009)
Cyclical and dose-dependent responses of adult human mature oligodendrocytes to fingolimod
Veronique E. Miron et al.
AMERICAN JOURNAL OF PATHOLOGY (2008)
FTY720 modulates human oligodendrocyte progenitor process extension and survival
Veronique E. Miron et al.
ANNALS OF NEUROLOGY (2008)
Astrocytes in multiple sclerosis: A product of their environment
A. Nair et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2008)
FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis
M. Mehling et al.
NEUROLOGY (2008)
Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: Consequences for mode of action in multiple sclerosis
Carolyn A. Foster et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2007)
FTY720 sustains and restores neuronal function in the DA rat model of MOG-induced experimental autoimmune encephalomyelitis
Balazs Balatoni et al.
BRAIN RESEARCH BULLETIN (2007)
Sphingosine 1-phosphate receptors in health and disease: Mechanistic insights from gene deletion studies and reverse pharmacology
Volker Brinkmann
PHARMACOLOGY & THERAPEUTICS (2007)
Patterns of contrast enhancement in the brain and meninges
James G. Smirniotopoulos et al.
RADIOGRAPHICS (2007)
Essential roles of sphingosine 1-phosphate/S1P(1) receptor axis in the migration of neural stem cells toward a site of spinal cord injury
Atsushi Kimura et al.
STEM CELLS (2007)
Multiple sclerosis: a battle between destruction and repair
Jonathan L. McQualter et al.
JOURNAL OF NEUROCHEMISTRY (2007)
Effects of LPA and SIP on the nervous system and implications for their involvement in disease
D. R. Herr et al.
CURRENT DRUG TARGETS (2007)
Oral fingolimod (FTY720) for relapsing multiple sclerosis
Ludwig Kappos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Intracellular sphingosine 1-phosphate mediates the increased excitability produced by nerve growth factor in rat sensory neurons
Y. H. Zhang et al.
JOURNAL OF PHYSIOLOGY-LONDON (2006)
Magnetic resonance imaging measures of brain atrophy in multiple sclerosis
VM Anderson et al.
JOURNAL OF MAGNETIC RESONANCE IMAGING (2006)
The measurement and clinical relevance of brain atrophy in multiple sclerosis
RA Bermel et al.
LANCET NEUROLOGY (2006)
Cortical demyelination and diffuse white matter injury in multiple sclerosis
A Kutzelnigg et al.
BRAIN (2005)
Edg8/S1P5: An oligodendroglial receptor with dual function on process retraction and cell survival
C Jaillard et al.
JOURNAL OF NEUROSCIENCE (2005)
Regeneration beyond the glial scar
J Silver et al.
NATURE REVIEWS NEUROSCIENCE (2004)
Sphingosine-1-phosphate induces proliferation and morphological changes of neural progenitor cells
J Harada et al.
JOURNAL OF NEUROCHEMISTRY (2004)
Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1
M Matloubian et al.
NATURE (2004)
Differential transactivation of sphingosine-1-phosphate receptors modulates NGF-induced neurite extension
RE Toman et al.
JOURNAL OF CELL BIOLOGY (2004)
Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice
M Webb et al.
JOURNAL OF NEUROIMMUNOLOGY (2004)
Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases
A Billich et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Remyelination in multiple sclerosis
W Brück et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2003)
Common signaling pathways link activation of murine PAR-1, LPA, and S1P receptors to proliferation of astrocytes
SD Sorensen et al.
MOLECULAR PHARMACOLOGY (2003)
The immune modulator FTY720 targets sphingosine 1-phosphate receptors
V Brinkmann et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis
A Chang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Astrocytes in chronic active multiple sclerosis plaques express MHC class II molecules
E Zeinstra et al.
NEUROREPORT (2000)